Medivir appoints Dr. Tom Morris as interim Chief Medical Officer

Rhea-AI Summary

Medivir AB has appointed Dr. Tom Morris as interim Chief Medical Officer as of October 5, 2020. Dr. Morris, who reports to CEO Yilmaz Mahshid, brings over 20 years of oncology experience from previous roles at Medeval Ltd and AstraZeneca. He has led clinical drug development programs globally and holds multiple degrees including a BSc in Physiology and medical degrees from the University of Wales. This leadership change aims to strengthen Medivir's oncology drug development efforts.

Positive

• Appointment of Dr. Tom Morris as interim CMO may bring fresh perspectives to the executive team.
• Dr. Morris's extensive experience in oncology and drug development could enhance Medivir's clinical programs.

Negative

• Management change may raise concerns about continuity in leadership during drug development phases.

STOCKHOLM, Oct. 5, 2020 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Dr. Tom Morris as interim Chief Medical Officer effective October 5, 2020. Dr. Morris will report to CEO Yilmaz Mahshid and join the Medivir Executive Team.

Tom Morris has more than 20 years of experience within drug development, mostly in oncology. Previously employed at Medeval Ltd and more recently at AstraZeneca. He has overseen the clinical development of several global drug programs, interacting with regulatory agencies, external clinical experts and academic groups worldwide. 

Dr. Morris holds a BSc in Physiology from the University of Wales, medical degrees from the University of Wales College of Medicine and Master of Laws degree from Cardiff Law School. Currently a fellow and Board member of The Faculty of Pharmaceutical Medicine, a former chair of its Ethical Issues committee and a member of its Professional Standards Committee.

For further information, please contact: 
Dr Yilmaz Mahshid
CEO
Medivir AB
phone: +46 (0)8 5468 3100.

About Medivir

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/medivir/r/medivir-appoints-dr--tom-morris-as-interim-chief-medical-officer,c3210320

The following files are available for download:

https://mb.cision.com/Main/652/3210320/1314850.pdf

Press release (PDF)

View original content:http://www.prnewswire.com/news-releases/medivir-appoints-dr-tom-morris-as-interim-chief-medical-officer-301145450.html

SOURCE Medivir

FAQ

Who is the new interim Chief Medical Officer at Medivir?

Dr. Tom Morris has been appointed as the interim Chief Medical Officer at Medivir, effective October 5, 2020.

What experience does Dr. Tom Morris bring to Medivir?

Dr. Morris has over 20 years of experience in oncology and drug development, previously holding positions at Medeval Ltd and AstraZeneca.

What is the impact of Dr. Morris's appointment on Medivir's drug development?

His extensive background in overseeing global drug programs may strengthen Medivir's efforts in developing innovative cancer treatments.

When did Dr. Tom Morris start his role at Medivir?

Dr. Tom Morris started his role as interim Chief Medical Officer on October 5, 2020.